Next Science Limited Stock Net Income
| NXSCF Stock | USD 0.01 0.01 50.00% |
As of the 11th of February 2026, Next Science secures the Downside Deviation of 45.51, mean deviation of 7.67, and Risk Adjusted Performance of 0.0566. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Next Science Limited, as well as the relationship between them. Please verify Next Science Limited downside deviation and the relationship between the information ratio and expected short fall to decide if Next Science Limited is priced some-what accurately, providing market reflects its recent price of 0.015 per share. As Next Science Limited appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.
Next Science's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Next Science's valuation are provided below:Next Science Limited does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Next |
Next Science 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Next Science's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Next Science.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Next Science on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Next Science Limited or generate 0.0% return on investment in Next Science over 90 days. Next Science is related to or competes with Charlottes Web, and High Sierra. Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address t... More
Next Science Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Next Science's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Next Science Limited upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 45.51 | |||
| Information Ratio | 0.0543 | |||
| Maximum Drawdown | 179.66 | |||
| Value At Risk | (22.73) | |||
| Potential Upside | 32.76 |
Next Science Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Next Science's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Next Science's standard deviation. In reality, there are many statistical measures that can use Next Science historical prices to predict the future Next Science's volatility.| Risk Adjusted Performance | 0.0566 | |||
| Jensen Alpha | 1.61 | |||
| Total Risk Alpha | (0.95) | |||
| Sortino Ratio | 0.0253 | |||
| Treynor Ratio | (0.27) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Next Science's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Next Science February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0566 | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 7.67 | |||
| Semi Deviation | 13.09 | |||
| Downside Deviation | 45.51 | |||
| Coefficient Of Variation | 1702.9 | |||
| Standard Deviation | 21.17 | |||
| Variance | 448.04 | |||
| Information Ratio | 0.0543 | |||
| Jensen Alpha | 1.61 | |||
| Total Risk Alpha | (0.95) | |||
| Sortino Ratio | 0.0253 | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 179.66 | |||
| Value At Risk | (22.73) | |||
| Potential Upside | 32.76 | |||
| Downside Variance | 2070.74 | |||
| Semi Variance | 171.3 | |||
| Expected Short fall | (51.87) | |||
| Skewness | 1.0 | |||
| Kurtosis | 12.72 |
Next Science Limited Backtested Returns
Next Science appears to be out of control, given 3 months investment horizon. Next Science Limited has Sharpe Ratio of 0.0135, which conveys that the firm had a 0.0135 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Next Science, which you can use to evaluate the volatility of the firm. Please exercise Next Science's Downside Deviation of 45.51, mean deviation of 7.67, and Risk Adjusted Performance of 0.0566 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Next Science holds a performance score of 1. The company secures a Beta (Market Risk) of -4.6, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Next Science are expected to decrease by larger amounts. On the other hand, during market turmoil, Next Science is expected to outperform it. Please check Next Science's downside variance, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Next Science's current price movements will revert.
Auto-correlation | 0.30 |
Below average predictability
Next Science Limited has below average predictability. Overlapping area represents the amount of predictability between Next Science time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Next Science Limited price movement. The serial correlation of 0.3 indicates that nearly 30.0% of current Next Science price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.3 | |
| Spearman Rank Test | -0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Next Science Limited reported net income of (9.35 Million). This is 102.74% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 101.64% higher than that of the company.
Next Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Next Science's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Next Science could also be used in its relative valuation, which is a method of valuing Next Science by comparing valuation metrics of similar companies.Next Science is currently under evaluation in net income category among its peers.
Next Fundamentals
| Return On Equity | -0.77 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.12) % | |||
| Operating Margin | (1.14) % | |||
| Current Valuation | 91.45 M | |||
| Shares Outstanding | 214.79 M | |||
| Shares Owned By Insiders | 52.54 % | |||
| Shares Owned By Institutions | 1.57 % | |||
| Price To Book | 7.22 X | |||
| Price To Sales | 9.21 X | |||
| Revenue | 8.95 M | |||
| Gross Profit | 6.94 M | |||
| EBITDA | (8.82 M) | |||
| Net Income | (9.35 M) | |||
| Cash And Equivalents | 11.06 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 1.34 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 5.40 X | |||
| Book Value Per Share | 0.07 X | |||
| Cash Flow From Operations | (8.26 M) | |||
| Earnings Per Share | (0.05) X | |||
| Beta | 0.64 | |||
| Market Capitalization | 112.89 M | |||
| Total Asset | 13.72 M | |||
| Z Score | 50.4 | |||
| Net Asset | 13.72 M |
About Next Science Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Next Science Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Next Science using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Next Science Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Next Pink Sheet
Next Science financial ratios help investors to determine whether Next Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Next with respect to the benefits of owning Next Science security.